Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 194.12% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 09/11/2023 | 188.24% | Guggenheim | $46 → $49 | Maintains | Buy |
| 08/14/2023 | 170.59% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 147.06% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 194.12% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 158.82% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 158.82% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 147.06% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 152.94% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 135.29% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 135.29% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 135.29% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 223.53% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 282.35% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 194.12% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 147.06% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 94.12% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 105.88% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 129.41% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/10/2023 | 194.12% | HC Wainwright & Co. | 42 美元 → 50 美元 | 維護 | 買 |
| 09/11/2023 | 188.24% | 古根海姆 | 46 美元 → 49 美元 | 維護 | 買 |
| 08/14/2023 | 170.59% | 古根海姆 | → 46 美元 | 重申 | 購買 → 購買 |
| 08/11/2023 | 147.06% | HC Wainwright & Co. | 50 美元 → 42 美元 | 維護 | 買 |
| 07/26/2023 | 194.12% | HC Wainwright & Co. | 44 美元 → 50 美元 | 維護 | 買 |
| 07/18/2023 | 158.82% | 威廉布萊爾 | → 44 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 06/26/2023 | 158.82% | HC Wainwright & Co. | 40 美元 → 44 美元 | 維護 | 買 |
| 06/16/2023 | 147.06% | 古根海姆 | 40 美元 → 42 美元 | 維護 | 買 |
| 05/18/2023 | — | 古根海姆 | 啓動覆蓋範圍開啓 | → 購買 | |
| 05/08/2023 | 152.94% | 奧本海默 | → 43 美元 | 重申 | → 跑贏大盤 |
| 03/15/2023 | 135.29% | HC Wainwright & Co. | → 40 美元 | 重申 | → 購買 |
| 08/01/2022 | 135.29% | 巴克萊 | → 40 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 12/21/2021 | 135.29% | HC Wainwright & Co. | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/23/2021 | 223.53% | 奧本海默 | → 55 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 8 月 10 日 | 282.35% | 雷蒙德·詹姆 | 50 美元 → 65 美元 | 維護 | 強勢買入 |
| 06/29/2021 | 194.12% | 雷蒙德·詹姆 | 39 美元 → 50 美元 | 維護 | 強勢買入 |
| 11/10/2020 | 147.06% | 拉登堡塔爾曼 | → 42 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 94.12% | B of A 類證券 | → 33 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 105.88% | 傑富瑞集團 | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 129.41% | 雷蒙德·詹姆 | → 39 美元 | 啓動覆蓋範圍開啓 | → 強勢買入 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的目標價格是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by HC Wainwright & Co. on November 10, 2023. The analyst firm set a price target for $50.00 expecting TARS to rise to within 12 months (a possible 194.12% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月10日公佈了塔蘇斯製藥（納斯達克股票代碼：TARS）的最新目標股價。該分析公司將目標股價定爲50.00美元，預計TARS將在12個月內升至12個月內（可能上漲194.12％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的最新分析師評級是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals maintained their buy rating.
Tarsus Pharmicals（納斯達克股票代碼：TARS）的最新分析師評級由HC Wainwright & Co. 提供，Tarsus Pharmicals維持買入評級。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與塔蘇斯製藥公司的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。塔蘇斯製藥的最新評級是在2023年11月10日公佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析師對Tarsus Pharmicals（TARS）的評級正確嗎？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $42.00 to $50.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $17.00, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但塔蘇斯製藥（TARS）的最新評級維持不變，目標股價爲42.00美元至50.00美元。塔蘇斯製藥（TARS）目前的交易價格爲17.00美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。